Thomas J. Herzfeld Advisors, Inc. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
Thomas J. Herzfeld Advisors, Inc. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2022$2,0000.0%300.0%0.00%0.0%
Q1 2022$2,000
-33.3%
300.0%0.00%0.0%
Q4 2021$3,0000.0%300.0%0.00%0.0%
Q3 2021$3,0000.0%300.0%0.00%0.0%
Q2 2021$3,0000.0%30
+36.4%
0.00%0.0%
Q1 2021$3,0000.0%22
+4.8%
0.00%0.0%
Q4 2020$3,000
+50.0%
21
+40.0%
0.00%0.0%
Q3 2020$2,000150.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2021
NameSharesValueWeighting ↓
Abingworth LLP 38,100$2,928,0001.67%
Opaleye Management Inc. 80,000$6,149,0001.59%
HIGHLINE CAPITAL MANAGEMENT, L.P. 410,000$31,517,0001.06%
Opus Point Partners Management, LLC 6,311$485,0001.05%
SECTOR GAMMA AS 68,015$5,228,0000.87%
Capital Impact Advisors, LLC 27,074$2,061,0000.76%
FORTALEZA ASSET MANAGEMENT INC/ 1,130$87,0000.71%
CAPITAL INTERNATIONAL LTD /CA/ 46,957$3,610,0000.63%
Virtus ETF Advisers LLC 8,794$676,0000.60%
Rock Springs Capital Management LP 200,000$15,374,0000.59%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders